Myeloid neoplasms with mixed proliferative and dysplastic features that do not meet the criteria for CMML, juvenile myelomonocytic leukemia, or aCML are classified as MDS/MPN-U. RARS-T, a provisional entity within the MDS/MPN-U subgroup, is clearly defined by the presence of marked ...
Pandrala et al., designed a novel inhibitor for CML with enhanced cardiac safety and low toxicity [1]. In acute myeloid leukemia (AML), efforts led to the discovery of a class of compounds with anti-mitotic activity based on the inhibition of tubulin polymerization [2]. These anti-tubulin...